The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 29, 2019

Primary Completion Date

December 6, 2022

Study Completion Date

December 6, 2022

Conditions

Cardiomyopathy, DilatedHeart FailureAutoantibodies

Interventions

DRUG

BC 007

1350 mg of BC 007

Trial Locations (3)

Bežanijska Kosa Clinical and Hospital Centre, Belgrade

Institut za kardiovaskularne bolesti Dedinje, Belgrade

Zvezdara Clinical and Hospital Centre, Belgrade